|
1
|
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
|
N Engl J Med
|
2007
|
10.06
|
|
2
|
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
|
Lancet Oncol
|
2011
|
3.95
|
|
3
|
Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients.
|
Cancer Prev Res (Phila)
|
2009
|
3.70
|
|
4
|
A phase II study of gefitinib in patients with advanced thyroid cancer.
|
Thyroid
|
2008
|
2.41
|
|
5
|
Response and acquired resistance to everolimus in anaplastic thyroid cancer.
|
N Engl J Med
|
2014
|
2.09
|
|
6
|
Human papillomavirus-associated adenocarcinoma of the base of the tongue.
|
Hum Pathol
|
2013
|
2.08
|
|
7
|
Thyroid carcinoma.
|
J Natl Compr Canc Netw
|
2010
|
2.02
|
|
8
|
Biomarkers of HPV in head and neck squamous cell carcinoma.
|
Cancer Res
|
2012
|
1.76
|
|
9
|
Dose to larynx predicts for swallowing complications after intensity-modulated radiotherapy.
|
Int J Radiat Oncol Biol Phys
|
2008
|
1.70
|
|
10
|
Head and neck cancers.
|
J Natl Compr Canc Netw
|
2011
|
1.64
|
|
11
|
A pilot surrogate endpoint biomarker study of celecoxib in oral premalignant lesions.
|
Cancer Prev Res (Phila)
|
2008
|
1.53
|
|
12
|
Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma.
|
Cancer Res
|
2013
|
1.51
|
|
13
|
Head and neck cancers, Version 2.2014. Clinical practice guidelines in oncology.
|
J Natl Compr Canc Netw
|
2014
|
1.39
|
|
14
|
Mouthwash use and cancer of the head and neck: a pooled analysis from the International Head and Neck Cancer Epidemiology Consortium.
|
Eur J Cancer Prev
|
2016
|
1.38
|
|
15
|
Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines.
|
J Natl Compr Canc Netw
|
2013
|
1.35
|
|
16
|
Dysphagia after sequential chemoradiation therapy for advanced head and neck cancer.
|
Otolaryngol Head Neck Surg
|
2006
|
1.18
|
|
17
|
Polymerase chain reaction detection of HPV in squamous carcinoma of the oropharynx.
|
Am J Clin Pathol
|
2010
|
1.11
|
|
18
|
Salivary gland tumors treated with adjuvant intensity-modulated radiotherapy with or without concurrent chemotherapy.
|
Int J Radiat Oncol Biol Phys
|
2010
|
1.10
|
|
19
|
Overcoming resistance to EGFR inhibitor in head and neck cancer: a review of the literature.
|
Oral Oncol
|
2012
|
1.06
|
|
20
|
Combined antegrade and retrograde esophageal dilation for head and neck cancer-related complete esophageal stenosis.
|
Laryngoscope
|
2010
|
1.06
|
|
21
|
Induction chemotherapy in locally advanced squamous cell cancer of the head and neck: evolution of the sequential treatment approach.
|
Semin Oncol
|
2004
|
1.05
|
|
22
|
Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck.
|
J Clin Oncol
|
2005
|
1.05
|
|
23
|
Organ preservation and treatment toxicity with induction chemotherapy followed by radiation therapy or chemoradiation for advanced laryngeal cancer.
|
Am J Clin Oncol
|
2005
|
1.05
|
|
24
|
Treatment of oral cavity squamous cell carcinoma with adjuvant or definitive intensity-modulated radiation therapy.
|
Int J Radiat Oncol Biol Phys
|
2011
|
1.02
|
|
25
|
Serum concentrations of interleukin-8, vascular endothelial growth factor, and epidermal growth factor receptor in patients with squamous cell cancer of the head and neck.
|
Oral Oncol
|
2005
|
1.01
|
|
26
|
beta-Tubulin-II expression strongly predicts outcome in patients receiving induction chemotherapy for locally advanced squamous carcinoma of the head and neck: a companion analysis of the TAX 324 trial.
|
J Clin Oncol
|
2009
|
1.00
|
|
27
|
Positron emission tomography with 18F-fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer.
|
Head Neck
|
2004
|
0.98
|
|
28
|
Induction chemotherapy in locally advanced head and neck cancer: a new standard of care?
|
Hematol Oncol Clin North Am
|
2008
|
0.98
|
|
29
|
Vandetanib for the treatment of medullary thyroid cancer.
|
Clin Cancer Res
|
2012
|
0.97
|
|
30
|
Medullary carcinoma.
|
J Natl Compr Canc Netw
|
2010
|
0.97
|
|
31
|
Efficacy and toxicity of reirradiation using intensity-modulated radiotherapy for recurrent or second primary head and neck cancer.
|
Cancer
|
2010
|
0.96
|
|
32
|
Relationship between radiation treatment time and overall survival after induction chemotherapy for locally advanced head-and-neck carcinoma: a subset analysis of TAX 324.
|
Int J Radiat Oncol Biol Phys
|
2011
|
0.96
|
|
33
|
Trastuzumab for the treatment of salivary duct carcinoma.
|
Oncologist
|
2013
|
0.94
|
|
34
|
Factors associated with smoking abstinence among smokers and recent-quitters with lung and head and neck cancer.
|
Lung Cancer
|
2011
|
0.94
|
|
35
|
Marital status and head and neck cancer outcomes.
|
Cancer
|
2014
|
0.93
|
|
36
|
Examining the need for neck dissection in the era of chemoradiation therapy for advanced head and neck cancer.
|
Arch Otolaryngol Head Neck Surg
|
2006
|
0.92
|
|
37
|
Acupuncture for dysphagia after chemoradiation therapy in head and neck cancer: a case series report.
|
Integr Cancer Ther
|
2010
|
0.90
|
|
38
|
Mucosal melanoma of the head and neck.
|
J Natl Compr Canc Netw
|
2012
|
0.89
|
|
39
|
Clinical practice guidance for radiotherapy planning after induction chemotherapy in locoregionally advanced head-and-neck cancer.
|
Int J Radiat Oncol Biol Phys
|
2009
|
0.89
|
|
40
|
Chemoradiation-induced cell loss in human submandibular glands.
|
Laryngoscope
|
2005
|
0.87
|
|
41
|
Phase 1b, multicenter, single blinded, placebo-controlled, sequential dose escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer receiving induction chemotherapy.
|
Cancer
|
2013
|
0.86
|
|
42
|
Acupuncture for dysphagia after chemoradiation in head and neck cancer: rationale and design of a randomized, sham-controlled trial.
|
Contemp Clin Trials
|
2012
|
0.86
|
|
43
|
Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer.
|
Oral Oncol
|
2012
|
0.85
|
|
44
|
Induction chemotherapy for locoregionally advanced head and neck cancer: past, present, future?
|
Oncologist
|
2013
|
0.84
|
|
45
|
Success of endoscopic pharyngoesophageal dilation after head and neck cancer treatment.
|
Laryngoscope
|
2013
|
0.83
|
|
46
|
Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy.
|
BMC Cancer
|
2014
|
0.82
|
|
47
|
Novel biomarker panel predicts prognosis in human papillomavirus-negative oropharyngeal cancer: an analysis of the TAX 324 trial.
|
Cancer
|
2011
|
0.82
|
|
48
|
Swallowing function following postchemoradiotherapy neck dissection: review of findings and analysis of contributing factors.
|
Otolaryngol Head Neck Surg
|
2011
|
0.82
|
|
49
|
Efficacy and toxicity of chemoradiotherapy using intensity-modulated radiotherapy for unknown primary of head and neck.
|
Int J Radiat Oncol Biol Phys
|
2010
|
0.81
|
|
50
|
Induction chemotherapy in head and neck cancer.
|
J Clin Oncol
|
2009
|
0.81
|
|
51
|
Human papillomavirus-associated oropharynx cancer (HPV-OPC): treatment options.
|
Curr Treat Options Oncol
|
2014
|
0.79
|
|
52
|
Novel agents for the treatment of mucositis.
|
J Support Oncol
|
2007
|
0.79
|
|
53
|
Anaplastic Thyroid Carcinoma, Version 2.2015.
|
J Natl Compr Canc Netw
|
2015
|
0.78
|
|
54
|
Seeking alternative biological therapies: the future of targeted molecular treatment.
|
Oral Oncol
|
2008
|
0.77
|
|
55
|
Metastatic human papillomavirus-positive nasopharyngeal carcinoma with an unusual pattern of aggressive hematogenous spread.
|
J Clin Oncol
|
2012
|
0.77
|
|
56
|
Utilizing computed tomography as a road map for designing selective and superselective neck dissection after chemoradiotherapy.
|
Otolaryngol Head Neck Surg
|
2010
|
0.77
|
|
57
|
Locally advanced head and neck cancer.
|
Am Soc Clin Oncol Educ Book
|
2013
|
0.77
|
|
58
|
Progress and perspectives in chemoprevention of head and neck cancer.
|
Expert Rev Anticancer Ther
|
2003
|
0.76
|
|
59
|
Concurrent weekly docetaxel and concomitant boost radiation therapy in the treatment of locally advanced squamous cell cancer of the head and neck.
|
Int J Radiat Oncol Biol Phys
|
2006
|
0.76
|
|
60
|
Nonsurgical treatment of laryngeal cancer.
|
N Engl J Med
|
2004
|
0.75
|
|
61
|
Re: Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation.
|
J Natl Cancer Inst
|
2009
|
0.75
|
|
62
|
Retropharyngeal nodes in hypopharynx cancer on positron emission tomography.
|
J Clin Oncol
|
2007
|
0.75
|
|
63
|
Behavior of oral squamous cell carcinoma in subjects with prior lichen planus.
|
Otolaryngol Head Neck Surg
|
2007
|
0.75
|